Synthesis, Pharmacological Evaluation, and Docking Studies of Novel Pyridazinone-Based Cannabinoid Receptor Type 2 Ligands-Reference-Cited by-同舟云学术

Synthesis, Pharmacological Evaluation, and Docking Studies of Novel Pyridazinone-Based Cannabinoid Receptor Type 2 Ligands

Published:2018-04-16 Issue:11 Volume:13 Page:1102-1114
ISSN:1860-7179
Container-title:ChemMedChem
language:en
Short-container-title:ChemMedChem

Author:

Ragusa Giulio¹,Bencivenni Serena²,Morales Paula³,Callaway Tyra³,Hurst Dow P.³,Asproni Battistina¹,Merighi Stefania²,Loriga Giovanni⁴,Pinna Gerard A.¹,Reggio Patricia H.³,Gessi Stefania²,Murineddu Gabriele¹^ORCID

Affiliation:

1. Department of Chemistry and Pharmacy; University of Sassari; via F. Muroni 23/A 07100 Sassari Italy

2. Dipartimento di Scienze Mediche, Sezione di Farmacologia; Università di Ferrara; Via Fossato di Mortara, 17-19 44121 Ferrara Italy

3. Department of Chemistry and Biochemistry; University of North Carolina at Greensboro; Greensboro NC 27402 USA

4. Institute of Translational Pharmacology; National Research Council; 09010 Pula Cagliari Italy

Funder

National Institutes of Health

Publisher

Wiley

Subject

Organic Chemistry,General Pharmacology, Toxicology and Pharmaceutics,Molecular Medicine,Drug Discovery,Biochemistry,Pharmacology

Reference51 articles.

1. Molecular characterization of a peripheral receptor for cannabinoids

2. Endocannabinoid Binding to the Cannabinoid Receptors: What Is Known and What Remains Unknown

3. Cannabinoid receptors and their ligands

4. Endocannabinoid signaling at the periphery: 50 years after THC

5. The pharmacology of cannabinoid receptors and their ligands: an overview

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Uridine-Derived 4-Aminophenyl 1-Thioglucosides: DFT Optimized FMO, ADME, and Antiviral Activities Study;BIOINTERFACE RES APP;2023

2. Uridine-Derived 4-Aminophenyl 1-Thioglucosides: DFT Optimized FMO, ADME, and Antiviral Activities Study;Biointerface Research in Applied Chemistry;2022-01-30

3. Rational drug design of CB2 receptor ligands: from 2012 to 2021;RSC Advances;2022